Connect your AI

AptarGroup ATR Accounts payable and other current liabilities

Accounts payable and other current liabilities at other companies

Halozyme TherapeuticsHALO

——

Other financials

Income statement

Revenue$982.9M+10.8%

Gross profit$351.9M+4.6%

Operating income$107.5M-5.2%

Net income$72.7M-7.8%

EPS (diluted)$1.12-4.3%

Balance sheet

Cash & equivalents$225.0M+78.8%

Total debt$1.4B+32.7%

Total equity$2.6B+3.6%

Total assets$5.1B+12.6%

Cash flow

Operating cash flow$118.7M+43.5%

CapEx$65.4M+15.0%

Free cash flow$53.3M+106%

Valuation

Market cap$7.68B-17.9%

Enterprise value$8.89B-13.9%

P/E19.9×-5.4×

P/S2×-0.6×

Profitability

Gross margin36.7%-1.6pp

Operating margin12.8%-1.2pp

Net margin10%-0.4pp

FCF margin8.4%-2.1pp

Returns & leverage

Return on equity15%-0.2pp

Debt / equity0.5×+0.1×

Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.

The official record: AptarGroup’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about AptarGroup's accounts payable and other current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AptarGroup's accounts payable and other current liabilities?: AptarGroup (ATR) reported accounts payable and other current liabilities of $36.42M in Q1 2026.
How has AptarGroup's accounts payable and other current liabilities changed year-over-year?: AptarGroup's accounts payable and other current liabilities increased by 9.3% year-over-year, from $33.32M to $36.42M.